Profitable Biotech Enters the Race to Treat Alzheimer's

What would you do if you had a money-printing machine that funded your biggest dreams?

Would you travel the world to far away countries?

Would you open a vineyard and create endless blends of award winning red wine?

What would you do if you had a blank check to explore your passions?

That seems like a pretty sweet gig.

So what if I told you there is a tiny NASDAQ biotech that has one of those machines...

And it's funding all of their R&D efforts in one of the most critical and important sectors to ever exist...

That's right. This tiny $3M biotech has a revenue generating subsidiary that pays for all of their research in helping find a treatment for Alzheimer's disease.

Not only does that de-risk this company from an investor standpoint...

But it could also offer a massive runway to discover a crucial treatment in the race to cure Alzheimer's.

Find out this profitable and potentially critical biotech now in this full report.

This message is a paid advertisement for InMed Pharmaceuticals Inc., (NASDAQ: INM) from i2i Marketing Group, LLC. It's Today Media, LLC. receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $7,500.00. Other than the compensation received for this advertisement sent to subscribers, It's Today Media and its principals are not affiliated with i2i Marketing Group, LLC. It's Today Media and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither It's Today Media nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from It's Today Media to buy or sell any security. It's Today Media has not evaluated the accuracy of any claims made in this advertisement. It's Today Media recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding InMed Pharmaceuticals Inc., (NASDAQ: INM) on i2iMarketing Group's website for additional information about the relationship between i2i Marketing Group and InMed Pharmaceuticals Inc., (NASDAQ: INM).